Norfloxacin, a new quinolone derivative which has good antimicrobial activity against most urinary pathogens, including gram-negative and gram-positive microorganisms (5-7) appears to be a promising agent for the treatment of urinary tract infections (5) . In this study, the penetration of norfloxacin into renal and prostatic tissue was evaluated in patients undergoing nephrectomy or prostatectomy.
Fifteen patients received one 400-mg tablet of norfloxacin between 21:00 h and 22:00 h the night before surgery and a second 400-mg tablet with their premedication about 1 h before the operation. Patient 2 was removed from the study because he had received trimethoprim-sulfamethoxazole within 72 h of surgery. Table 1 With the exception of one sample (patient 2), no antibiotics were detected in any of the urine taken before the administration of norfloxacin. Although norfloxacin was undetectable in the serum of patient 10, the concentration in his urine was 87 ,ug ml-'. The levels'of norfloxacin in the kidney parenchyma were strikingly higher than in prostatic tissue and reached values up to 12 times the levels in serum. The drug was distributed throughout all three regions of the kidney, i.e., cortex, medulla, and papilla (Table 2) . Norfloxacin was detectable in 9 of the 10 prostate specimens obtained by TUR. The mean concentration in the 10 patients was 1.6 ± 0.4 pag g-1. In the tissue removed by suprapubic prostatectomy, the concentration of norfloxacin was 2.55 ug g-1. The lower value observed durin'g TUR can be explained by the dilution of the antibiotic owing to repeated tissue flushing during the course of transurethral procedure. All patients tolerated the drug very well, and no side effect was noted.
The present study demonstrates that norfloxacin, which is now used in clinical trials in upper and lower urinary tract infections (4, 8, 9) 
19-23, 1983
). Although 30% of the total dose of norfloxacin administered is excreted unchanged in the urine, approximately 8 to 10% is metabolized drugs. Of these metabolites, M3 has about 1/5 of the microbiological activity of norfloxacin, and there might have been some minor interference with the biological assay. We cannot exclude the possibility that we could have under-or overestimated the concentrations within the urine or even the kidneys.
Thus, this investigation suggests that this antibiotic readily diffuses from serum into prostatic tissue. Its low protein binding (5%), its high lipid solubility (1), and its zwitterion nature with pKa's of 6.4 and 8.7 may favor entrapment in the human prostatic environment, in which the pH is 7.28 ± 0.04 for the normal individual (3). Of most importance in this study was the observation that norfloxacin concentrations in serum, cortex, medulla, papilla, and prostate were significantly greater than the MICs for most urinary pathogens (5), suggesting that this new quinolone may be effective in the treatment of severe prostatitis and pyelonephritis.
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